RegisterLogin

DA-0157

CAT: 0804-HY-170928Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-170928Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
DA-0157 is the orally active inhibitor for EGFR and ALK that overcomes drug-resistant mutations of EGFR C797S and ALK in NSCLC) cells. DA-0157 inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50 = 6.9 nM), Ba/F3-EGFR WT (IC50 = 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50 = 5.5 nM), and Ba/F3-EML4-ALK (IC50 = 7.4 nM) . DA-0157 inhibits CYP2D6 with IC50 of 5.26 μM. DA-0157 exhibits antitumor efficacy in mouse models[1].
CAS Number
[2756978-82-0]
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK) ; Cytochrome P450; EGFR
Related Pathways
JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
CN1CCN(C2CCN(C3=C(C)C=C(NC4=NC(NC5=C(P(C)(C)=O)C=C(C)C=C5)=C(Br)C=N4)C(OC)=C3)CC2)CC1
Molecular Formula
C31H43BrN7O2P
Molecular Weight
656.60
References & Citations
[1]He P, et al., Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR/ALK co-mutations. Eur J Med Chem. 2025 Apr 5;287:117323.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-125610DA-3934
HY-162454DA-023
HY-122148DA 4626
HY-162158DA ZP1
HY-120203DA 1131
HY-167894DA-8031
HY-P3255-01DA-JC4
HY-120730DA 1686
HY-147097EDA-DA
HY-117742DA-7867

Alternative Products

CatalogName
T205118-01DA-0157
IL-0157-HP-BULKIoLiLyt 0157
IL-0157-HP-0250IoLiLyt 0157, 250 g
IL-0157-HP-0500IoLiLyt 0157, 500 g
IL-0157-HP-5000IoLiLyt 0157, 5 kg
IL-0157-HP-1000IoLiLyt 0157, 1 kg
IL-0157-HP-0025IoLiLyt 0157, 25 g
IL-0157-HP-0050IoLiLyt 0157, 50 g
IL-0157-HP-0100IoLiLyt 0157, 100 g
MBS5316867-01Escherichia coli 0157 Antibody

Popular Products